NeoGenomics Laboratories

NeoGenomics Laboratories Our tagline: Answers are in our DNA™
Our vision: A world where every cancer treatment decision is as personal as the patient.

NeoGenomics Laboratories is a premier cancer diagnostics and pharma services company dedicated to saving lives by improving patient care. NeoGenomics serves oncologists, pathologists, pharmaceutical companies, academic centers, and others with innovative diagnostic, prognostic and predictive testing. At NeoGenomics, we team up with our clients to solve the challenges of making precise diagnoses, a

id in bringing new therapies to market, and finding the unique hallmarks of each patient’s disease that point the way to proper treatment.

See the impact of diverse population data: neogenomics.com/oncology-data-solutions. Tap into a dataset representing the ...
08/31/2026

See the impact of diverse population data: neogenomics.com/oncology-data-solutions. Tap into a dataset representing the entire U.S. population—over 3M patient profiles from 4,400 healthcare organizations.

Therapeutic response in AML extends beyond traditional clinical endpoints. Our AML NanoMRD™ solution provides a deeper v...
08/28/2026

Therapeutic response in AML extends beyond traditional clinical endpoints.

Our AML NanoMRD™ solution provides a deeper view of disease dynamics over time, helping characterize treatment impact at the biological level. Contact us to learn more: [email protected].

Our scientific expertise and comprehensive oncology biomarker portfolio include newly validated, off-the-shelf B7-H3, CD...
08/27/2026

Our scientific expertise and comprehensive oncology biomarker portfolio include newly validated, off-the-shelf B7-H3, CD137, EZH2, PRMT5, and TROP2 biomarkers to help teams design smarter trials with greater confidence in patient stratification strategies. Contact us to learn more: [email protected].

NeoGenomics has improved turnaround times for Neo Comprehensive® – Heme Cancers and Neo Comprehensive® – Myeloid Disorde...
08/25/2026

NeoGenomics has improved turnaround times for Neo Comprehensive® – Heme Cancers and Neo Comprehensive® – Myeloid Disorders to as few as 8 days*.

The same comprehensive, clinically actionable insights you trust are now available faster. Learn more: https://www.neogenomics.com/providers/oncology-solutions/hematological-cancer

*Turnaround time for these tests is 8–11 days.

Our  AML NanoMRD™ solution delivers high-sensitivity AML MRD detection down to 0.01% (10⁻⁴). This enables detection of c...
08/21/2026

Our AML NanoMRD™ solution delivers high-sensitivity AML MRD detection down to 0.01% (10⁻⁴).

This enables detection of clinically relevant low-level disease burden, supporting relapse-risk evaluation, and robust MRD monitoring in AML studies even from challenging samples. Contact us to learn more: [email protected].

Our expanding biomarker portfolio includes newly validated, off-the-shelf biomarkers B7-H3, CD137, EZH2, PRMT5, and TROP...
08/19/2026

Our expanding biomarker portfolio includes newly validated, off-the-shelf biomarkers B7-H3, CD137, EZH2, PRMT5, and TROP2, to help biopharma teams gain actionable insights for advanced target expression profiling and patient stratification. Contact us to learn more: [email protected].

Address

9490 NeoGenomics Way
Fort Myers, FL
33912

Alerts

Be the first to know and let us send you an email when NeoGenomics Laboratories posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Contact The Business

Send a message to NeoGenomics Laboratories:

Shortcuts

Share